Crizanlizumab Prevents Sickle Cell Pain Crises
In a randomized trial of patients with sickle cell disease recently published in New England Journal of Medicine, the P-selectin inhibitor crizanlizumab resulted in a significantly lower rate of disease-related pain crises than placebo. Hydroxyurea is currently the only drug that modifies the natural history of the disease, but it doesn't prevent pain crises. In the intention-to-treat analysis, patients in the high-dose crizanlizumab group had a 45.3% lower rate of pain crises annually relative to placebo (median 1.63 vs 2.98) and the low-dose crizanlizumab group had a 32.6% lower rate of pain crises compared with placebo. The median time to the first crisis was significantly longer with high-dose crizanlizumab than with placebo (4.07 vs 1.38 months), as was the median time to the second crisis (10.32 vs 5.09 months)..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:317 |
|---|---|
| Enthalten in: |
The journal of the American Medical Association / Englische Ausgabe - 317(2017), 8, Seite 798-798 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Slomski, Anita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical trials |
|---|
| doi: |
10.1001/jama.2017.0355 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1992078548 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1992078548 | ||
| 003 | DE-627 | ||
| 005 | 20230715040324.0 | ||
| 007 | tu | ||
| 008 | 170512s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jama.2017.0355 |2 doi | |
| 028 | 5 | 2 | |a PQ20170721 |
| 035 | |a (DE-627)OLC1992078548 | ||
| 035 | |a (DE-599)GBVOLC1992078548 | ||
| 035 | |a (PRQ)a1517-860031fed7d74e7578d655f5cf75c8b39c73a19e2c52b1780b6e5b4e39f550bb0 | ||
| 035 | |a (KEY)0027940420170000317000800798crizanlizumabpreventssicklecellpaincrises | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 100 | 1 | |a Slomski, Anita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Crizanlizumab Prevents Sickle Cell Pain Crises |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a In a randomized trial of patients with sickle cell disease recently published in New England Journal of Medicine, the P-selectin inhibitor crizanlizumab resulted in a significantly lower rate of disease-related pain crises than placebo. Hydroxyurea is currently the only drug that modifies the natural history of the disease, but it doesn't prevent pain crises. In the intention-to-treat analysis, patients in the high-dose crizanlizumab group had a 45.3% lower rate of pain crises annually relative to placebo (median 1.63 vs 2.98) and the low-dose crizanlizumab group had a 32.6% lower rate of pain crises compared with placebo. The median time to the first crisis was significantly longer with high-dose crizanlizumab than with placebo (4.07 vs 1.38 months), as was the median time to the second crisis (10.32 vs 5.09 months). | ||
| 650 | 4 | |a Inhibitor drugs | |
| 650 | 4 | |a Pain management | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Sickle cell disease | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of the American Medical Association / Englische Ausgabe |d Chicago, Ill. : American Medical Association, 1883 |g 317(2017), 8, Seite 798-798 |w (DE-627)129077798 |w (DE-600)2958-0 |w (DE-576)014410338 |x 0254-9077 |7 nnns |
| 773 | 1 | 8 | |g volume:317 |g year:2017 |g number:8 |g pages:798-798 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1001/jama.2017.0355 |3 Volltext |
| 856 | 4 | 2 | |u http://dx.doi.org/10.1001/jama.2017.0355 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1876430747 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_252 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4082 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4309 | ||
| 951 | |a AR | ||
| 952 | |d 317 |j 2017 |e 8 |h 798-798 | ||